Merus
1D
1W
1M
3M
YTD
1Y
5Y
ALL
Why Robinhood?
You can watch Merus and buy or sell other stocks, ETFs, and their options commission-free!About MRUS
Merus NV is a clinical-stage immuno-oncology company, which engages in the discovery and development of bispecific antibody therapeutics. Its pipeline includes Biclonics for solid and hematological tumors.
CEOJan G. J. van de Winkel
CEOJan G. J. van de Winkel
Employees260
Employees260
HeadquartersUtrecht, Utrecht
HeadquartersUtrecht, Utrecht
Founded2003
Founded2003
Employees260
Employees260
MRUS Key Statistics
Market cap6.83B
Market cap6.83B
Price-Earnings ratio-16.87
Price-Earnings ratio-16.87
Dividend yield—
Dividend yield—
Average volume343.50K
Average volume343.50K
High today—
High today—
Low today—
Low today—
Open price—
Open price—
Volume0.00
Volume0.00
52 Week high$97.14
52 Week high$97.14
52 Week low$33.19
52 Week low$33.19
Stock Snapshot
With a market cap of 6.83B, Merus(MRUS) trades at $90.00. The stock has a price-to-earnings ratio of -16.87.
On 2026-01-12, Merus(MRUS) shares started trading at —, with intraday highs of — and lows of —.
Trading volume for Merus(MRUS) stock has reached 0, versus its average volume of 343.5K.
Over the past 52 weeks, Merus(MRUS) stock has traded between a high of $97.14 and a low of $33.19.
Over the past 52 weeks, Merus(MRUS) stock has traded between a high of $97.14 and a low of $33.19.
People also own
Based on the portfolios of people who own MRUS. This list is generated using Robinhood data, and it’s not a recommendation.